Production of clinical-grade recombinant adeno-associated virus vectors

Current Opinion in Biotechnology

Volumn 13, Issue 5, 2002, Pages 418-423

  Snyder, Richard O ^a   Flotte, Terence R ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA POLYMERASE; NUCLEOTIDE; PLASMID VECTOR; RECOMBINANT DNA; TRANSMEMBRANE CONDUCTANCE REGULATOR; VIRUS PROTEIN; VIRUS VECTOR;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; CELL DEATH; CELL DIVISION; CYTOLYSIS; DNA REPLICATION; EPITHELIUM CELL; GAMMA IRRADIATION; GENE EXPRESSION; GENE FUNCTION; GENE SEQUENCE; GENE STRUCTURE; GENE TARGETING; GENETIC TRANSCRIPTION; HELPER VIRUS; HERPES VIRUS; HERPES VIRUS TYPE 6; HUMAN; INVERTED TERMINAL REPEAT; LIVER CELL; NERVE CELL; NONHUMAN; PARVOVIRIDAE DEPENDOVIRUS; PARVOVIRUS; PRIORITY JOURNAL; PROMOTER REGION; RETINA CELL; REVIEW; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS GENE; VIRUS INFECTION; VIRUS REPLICATION; X IRRADIATION;

ADENO-ASSOCIATED VIRUS; ANIMALIA; DEPENDOVIRUS; DNA VIRUSES; HERPESVIRIDAE; PARVOVIRIDAE; PARVOVIRUS;

EID: 0036811528     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(02)00369-5     Document Type: Review

References (57)

1. Blacklow N.R., Hoggan M.D., Kapikian A.Z., Austin J.B., Rowe W.P. Epidemiology of adenovirus-associated virus infection in a nursery population. Am J Epidemiol. 88:1968;368-378.
2. Blacklow N.R. Adeno-associated viruses of humans. Pattison J.R. Parvoviruses and Human Disease. 1988;165-174 CRC Press.
3. Weindler F.W., Heilbronn R. A subset of herpes simplex virus replication genes provides helper functions for productive adeno-associated virus replication. J Virol. 65:1991;2476-2483.
4. Thomson B.J., Efstathiou S., Honess R.W. Acquisition of the human adeno-associated virus type-2 rep gene by human herpesvirus type-6. Nature. 351:1991;78-80.
5. Yakinoglu A.O., Heilbronn R., Burkle A., Schlehofer J.R., zur Hausen H. DNA amplification of adeno-associated virus as a response to cellular genotoxic stress. Cancer Res. 48:1988;3123-3129.
6. Im D.S., Muzyczka N. The AAV origin binding protein Rep68 is an ATP-dependent site-specific endonuclease with DNA helicase activity. Cell. 61:1990;447-457.
7. Kotin R.M., Siniscalco M., Samulski R.J., Zhu X.D., Hunter L., Laughlin C.A., McLaughlin S., Muzyczka N., Rocchi M., Berns K.I. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA. 87:1990;2211-2215.
8. Weitzman M.D., Kyostio S.R., Kotin R.M., Owens R.A. Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA. Proc Natl Acad Sci USA. 91:1994;5808-5812.
9. Urcelay E., Ward P., Wiener S.M., Safer B., Kotin R.M. Asymmetric replication in vitro from a human sequence element is dependent on adeno-associated virus Rep protein. J Virol. 69:1995;2038-2046.
10. Pereira D.J., McCarty D.M., Muzyczka N. The adeno-associated virus (AAV) Rep protein acts as both a repressor and an activator to regulate AAV transcription during a productive infection. J Virol. 71:1997;1079-1088.
11. Labow M.A., Hermonat P.L., Berns K.I. Positive and negative autoregulation of the adeno-associated virus type 2 genome. J Virol. 60:1986;251-258.
12. Redemann B.E., Mendelson E., Carter B.J. Adeno-associated virus Rep protein synthesis during productive infection. J Virol. 63:1989;873-882.
13. Pereira D.J., Muzyczka N. The cellular transcription factor SP1 and an unknown cellular protein are required to mediate Rep protein activation of the adeno-associated virus p19 promoter. J Virol. 71:1997;1747-1756.
14. Samulski R.J., Chang L.S., Shenk T. Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J Virol. 63:1989;3822-3828.
15. Ferrari F.K., Xiao X., McCarty D., Samulski R.J. New developments in the generation of Ad-free, high-titer rAAV gene therapy vectors. Nat Med. 3:1997;1295-1297. Describes increases in vector yield and improvements in purity by elimination of infectious adenovirus.
16. Grimm D., Kern A., Pawlita M., Ferrari F., Samulski R., Kleinschmidt J. Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Ther. 6:1999;1322-1330.
17. Gao G.P., Qu G., Faust L.Z., Engdahl R.K., Xiao W., Hughes J.V., Zoltick P.W., Wilson J.M. High-titer adeno-associated viral vectors from a Rep/Cap cell line and hybrid shuttle virus. Hum Gene Ther. 9:1998;2353-2362. Celllinebased approach in which the rAAV vector cassette is delivered in a recombinant adenovirus shuttle.
18. Clark K.R., Voulgaropoulou F., Johnson P.R. A stable cell line carrying adenovirus-inducible rep and cap genes allows for infectivity titration of adeno-associated virus vectors. Gene Ther. 3:1996;1124-1132. Describes a cell-line-based approach to the infectious center assay which greatly improves the rigor of quality control.
19. Liu X.L., Clark K.R., Johnson P.R. Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirus. Gene Ther. 6:1999;293-299.
20. Chadeuf G., Favre D., Tessier J., Provost N., Nony P., Kleinschmidt J., Moullier P., Salvetti A. Efficient recombinant adeno-associated virus production by a stable rep-cap HeLa cell line correlates with adenovirus-induced amplification of the integrated rep-cap genome. J Gene Med. 2:2000;260-268.
21. Mathews L.C., Gray J.T., Gallagher M.R., Snyder R.O. Recombinant adeno-associated viral vector production using stable packaging and producer cell lines. Methods Enzymol. 346:2002;393-413.
22. Conway J.E., Zolotukhin S., Muzyczka N., Hayward G.S., Byrne B.J. Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by a herpes simplex virus type 1 amplicon expressing Rep and Cap. J Virol. 71:1997;8780-8789.
23. Conway J., Rhys C., Zolotukhin I., Zolotukhin S., Muzyczka N., Hayward G., Byrne B. High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and Cap. Gene Ther. 6:1999;986-993. Describes a promising new approach, based on herpes virus, which eliminates the need for transfection.
24. Clark K.R., Liu X., McGrath J.P., Johnson P.R. Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses. Hum Gene Ther. 10:1999;1031-1039.
25. Gao G., Qu G., Burnham M.S., Huang J., Chirmule N., Joshi B., Yu Q.C., Marsh J.A., Conceicao C.M., Wilson J.M. Purification of recombinant adeno-associated virus vectors by column chromatography and its performance in vivo. Hum Gene Ther. 11:2000;2079-2091.
26. Auricchio A., Hildinger M., O'Connor E., Gao G.P., Wilson J.M. Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. Hum Gene Ther. 12:2001;71-76.
27. Zolotukhin S., Byrne B.J., Mason E., Zolotukhin I., Potter M., Chesnut K., Summerford C., Samulski R.J., Muzyczka N. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 6:1999;973-985. Describes the advantages of column chromatography techniques in terms of present infectious titer.
28. Xiao X., Li J., Samulski R.J. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol. 70:1996;8098-8108.
29. Guy J., Qi X., Muzyczka N., Hauswirth W.W. Reporter expression persists 1 year after adeno-associated virus-mediated gene transfer to the optic nerve. Arch Ophthalmol. 117:1999;929-937.
30. During M.J., Leone P. Adeno-associated virus vectors for gene therapy of neurodegenerative disorders. Clin Neurosci. 3:1995;292-300.
31. During M.J., Samulski R.J., Elsworth J.D., Kaplitt M.G., Leone P., Xiao X., Li J., Freese A., Taylor J.R., Roth R.H., et al. In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector. Gene Ther. 5:1998;820-827.
32. Mandel R.J., Spratt S.K., Snyder R.O., Leff S.E. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc Natl Acad Sci USA. 94:1997;14083-14088.
33. Bankiewicz K.S., Leff S.E., Nagy D., Jungles S., Rokovich J., Spratt K., Cohen L., Libonati M., Snyder R.O., Mandel R.J. Practical aspects of the development of ex vivo and in vivo gene therapy for Parkinson's disease. Exp Neurol. 144:1997;147-156.
34. Snyder R.O., Miao C.H., Patijn G.A., Spratt S.K., Danos O., Nagy D., Gown A.M., Winther B., Meuse L., Cohen L.K., et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet. 16:1997;270-276. The primary proof-of-concept supporting the potential efficiency and longevity of rAAV-mediated gene delivery to the liver.
35. Snyder R.O., Miao C., Meuse L., Tubb J., Donahue B.A., Lin H.F., Stafford D.W., Patel S., Thompson A.R., Nichols T., et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med. 5:1999;64-70.
36. Song S., Embury J., Laipis P.J., Berns K.I., Crawford J.M., Flotte T.R. Stable therapeutic serum levels of human (-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors. Gene Ther. 8:2001;1299-1306.
37. Flotte T.R., Afione S.A., Conrad C., McGrath S.A., Solow R., Oka H., Zeitlin P.L., Guggino W.B., Carter B.J. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc Natl Acad Sci USA. 90:1993;10613-10617.
38. Flotte T.R., Afione S.A., Solow R., Drumm M.L., Markakis D., Guggino W.B., Zeitlin P.L., Carter B.J. Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter. J Biol Chem. 268:1993;3781-3790.
39. Zabner J., Seiler M., Walters R., Kotin R.M., Fulgeras W., Davidson B.L., Chiorini J.A. Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. J Virol. 74:2000;3852-3858.
40. Kearns W.G., Afione S.A., Fulmer S.B., Pang M.C., Erikson D., Egan M., Landrum M.J., Flotte T.R., Cutting G.R. Recombinant adeno-associated virus (AAV-CFTR) vectors do not integrate in a site-specific fashion in an immortalized epithelial cell line. Gene Ther. 3:1996;748-755.
41. Song S., Laipis P.J., Berns K.I., Flotte T.R. Effect of DNA-dependent protein kinase on the molecular fate of the rAAV2 genome in skeletal muscle. Proc Natl Acad Sci USA. 98:2001;4084-4088.
42. Miao C.H., Nakai H., Thompson A.R., Storm T.A., Chiu W., Snyder R.O., Kay M.A. Nonrandom transduction of recombinant adeno-associated virus vectors in mouse hepatocytes in vivo: cell cycling does not influence hepatocyte transduction. J Virol. 74:2000;3793-3803.
43. Flotte T., Carter B., Conrad C., Guggino W., Reynolds T., Rosenstein B., Taylor G., Walden S., Wetzel R. A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease. Hum Gene Ther. 7:1996;1145-1159.
44. Wagner J.A., Reynolds T., Moran M.L., Moss R.B., Wine J.J., Flotte T.R., Gardner P. Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus. Lancet. 351:1998;1702-1703. The first published results from an rAAV vector clinical trial.
45. Wagner J.A., Moran M.L., Messner A.H., Daifuku R., Conrad C.K., Reynolds T., Guggino W.B., Moss R.B., Carter B.J., Wine J.J., et al. A phase I/II study of tgAAV-CF for the treatment of chronic sinusitis in patients with cystic fibrosis. Hum Gene Ther. 9:1998;889-909.
46. Wagner J.A., Nepomuceno I.B., Messner A.H., Moran M.L., Batson E.P., Desch J.K., Norbash A.M., Conrad C.K., Guggino W.B., Flotte T.R., et al. A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in CF patients with antrostomies. Hum Gene Ther. 13:2002;1349-1359.
47. Song S., Morgan M., Ellis T., Poirier A., Chesnut K., Wang J., Brantly M., Muzyczka N., Byrne B.J., Atkinson M., et al. Sustained secretion of human (1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. Proc Natl Acad Sci USA. 95:1998;14384-14388.
48. Herzog R.W., Hagstrom J.N., Kung S.H., Tai S.J., Wilson J.M., Fisher K.J., High K.A. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci USA. 94:1997;5804-5809.
49. Kay M.A., Manno C.S., Ragni M.V., Larson P.J., Couto L.B., McClelland A., Glader B., Chew A.J., Tai S.J., Herzog R.W., et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet. 24:2000;257-261.
50. Halbert C.L., Rutledge E.A., Allen J.M., Russell D.W., Miller A.D. Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes. J Virol. 74:2000;1524-1532.
51. Samulski R.J., Zhu X., Xiao X., Brook J.D., Housman D.E., Epstein N., Hunter L.A. Targeted integration of adeno-associated virus (AAV) into human chromosome 19. [published erratum appears in EMBO J, 1992. 11:128]. EMBO J. 10:1991;3941-3950.
52. Ponnazhagan S., Mukherjee P., Yoder M.C., Wang X.S., Zhou S.Z., Kaplan J., Wadsworth S., Srivastava A. Adeno-associated virus 2-mediated gene transfer in vivo: organ-tropism and expression of transduced sequences in mice. Gene. 190:1997;203-210.
53. Miao C.H., Snyder R.O., Schowalter D.B., Patijn G.A., Donahue B., Winther B., Kay M.A. The kinetics of rAAV integration in the liver. Nat Genet. 19:1998;13-15.
54. Nakai H., Yant S.R., Storm T.A., Fuess S., Meuse L., Kay M.A. Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J Virol. 75:2001;6969-6976.
55. Rizzuto G., Gorgoni B., Cappelletti M., Lazzaro D., Gloaguen I., Poli V., Sgura A., Cimini D., Ciliberto G., Cortese R., et al. Development of animal models for adeno-associated virus site-specific integration. J Virol. 73:1999;2517-2526.
56. Dutheil N., Shi F., Dupressoir T., Linden R.M. Adeno-associated virus site-specifically integrates into a muscle-specific DNA region. Proc Natl Acad Sci USA. 97:2000;4862-4866.
57. Wu P., Phillips M.I., Bui J., Terwilliger E.F. Adeno-associated virus vector-mediated transgene integration into neurons and other nondividing cell targets. J Virol. 72:1998;5919-5926.